A new adenoviral vector (Ad-GFAP-GDNF) (Ad-¼ adenovirus, GFAP ¼ glial fibrillary acidic protein, GDNF ¼ glial cell line-derived neurotrophic factor) was constructed in which (i) the E1,E3/E4 regions of Ad5 were deleted and (ii) the GDNF transgene is driven by the GFAP promoter. We verified, in vitro, that the recombinant GDNF was expressed in primary cultures of astrocytes. In vivo, the Ad-GFAP-GDNF was injected into the striatum of rats 1 week before provoking striatal 6-OHDA lesion. After 1 month, the striatal GDNF levels were 37 pg/mg total protein. This quantity was at least 120-fold higher than in nontransduced striatum or after injection of the empty adenoviral vector. At 3 months after viral injection, GDNF expression decreased, whereas the viral DNA remained unchanged. Furthermore, around 70% of the dopaminergic (DA) neurons were protected from degeneration up to 3 months as compared to about 45% in the control groups. In addition, the amphetamine-induced rotational behavior was decreased. The results obtained in this study on DA neuron protection and rotational behavior are similar to those previously reported using vectors with viral promoters. In addition to these results, we established that a high level of GDNF was present in the striatum and that the period of GDNF expression was prolonged after injection of our adenoviral vector.
Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder. It is characterized by tremor, bradykinesia, rigidity and postural instability that result from a loss of dopaminergic (DA) neurons of the nigrostriatal pathway. The best current therapy of PD is the administration of L-Dopa. However, L-Dopa loses its effectiveness as the disease progresses. Different therapeutic approaches are therefore being investigated such as the use of neurotrophic factors, [1] [2] [3] [4] cell/tissue transplantation [5] [6] [7] and gene transfer of trophic factors using recombinant adenovirus, recombinant adenoassociated virus (AAV) or lentivirus. 8, 9 The ultimate goal of these approaches would be to arrest or to slow down the progressive degenerative process of the disease.
Previous research in our laboratory 10, 11 and in others 12 revealed that the progressive degeneration of DA neurons in an adult rat model of PD, 13 using an E1/E3 defective adenovirus (first-generation virus) encoding glial cell line-derived neurotrophic factor (GDNF), under a viral promoter was reduced. The effects obtained in vivo depend on the time and site of administration of recombinant virus. 14, 15 Although these results were encouraging for gene therapy, the first-generation adenovirus had a toxic effect for transduced cells by inducing the synthesis of viral proteins within these cells. These proteins elicit an immune response in the injected brains, which generates toxicity. It is probable that the toxicity of the E1/E3 defective virus is due to the E4 region of the type 5 adenovirus which is present in the recombinant virus.
Yeh et al 16 suggested that, in vivo, a low level of E4 expression could be cytotoxic to the recipient cells. In fact, Dedieu et al 17 demonstrated that the E1,E3/E4 defective adenovirus (third generation) was less toxic for transduced cells than the 'first-generation' E1/E3 defective virus. In addition, the infusion of E1,E3/E4 defective virus elicited lower inflammatory responses, improved local tolerance and increased viral DNA persistence in the liver of a lacZ-transgenic mouse. Thus, an E1,E3/E4 defective adenovirus represents progression on the path toward preclinical therapy.
The aim of our work was to use the E1,E3/E4 defective adenovirus to deliver GDNF, a therapeutic gene, into the brain of a rat model of PD. The expression of GDNF was targeted to the astrocytes in the lesioned striatum. Astrocytes are the most abundant glial cells in the central nervous system (CNS), and are necessary for the survival of neurons in vivo 18 and in vitro. 19 These cells produce and secrete several growth factors, and among them, GDNF and cytokines. [20] [21] [22] [23] In addition, following brain injury, the glial fibrillary acidic protein (GFAP) gene is upregulated in reactive astrocytes. 24 We therefore used the promoter of the GFAP gene, whose expression in the CNS is restricted to astrocytes, 24, 25 to drive GDNF gene expression. Restriction of GDNF expression to a specific cell type limits the side effects caused by the expression of this gene in surrounding cells, thus facilitating the long-term expression of the transgene. Our results unequivocally showed that the recombinant Ad-GFAP-GDNF, in which the transgene was driven by a glial-specific promoter, prevented DA neurons death after striatal lesions induced by 6-OHDA in the rats and improved the drug-induced rotational behavior. As compared to the E1/E3 deleted adenovirus used previously in our laboratory, the cytotoxicity in injected animals was much lower.
Results
In this work we constructed an E1,E3/E4 defective recombinant adenovirus encoding rat GDNF under the control of a specific glial promoter, GFAP, by homologous recombination in Escherichia coli (see Materials and methods). This defective virus exhibits a large deletion in the E4 region, which abrogates the synthesis of all E4-encoded gene products. 17 The virus was generated in the IGRP2 cell line that transcomplements the E4 viral function. 16 
In vitro experiments
The ability of the recombinant Ad-GFAP-GDNF to express GDNF was first tested in primary cultures of astrocytes. The neurotrophic effect of this secreted protein on the survival of DA neurons was performed on mesencephalic cultures.
Synthesis of GDNF by various types of cells. To determine whether astrocytes transduced with Ad-GFAP-GDNF express recombinant GDNF, cultivated rat astrocytes were infected with the recombinant virus as well as an empty control at different doses. Conditioned medium (CM) and cellular pellets were collected at 4, 6 and 8 days after infection for analysis by ELISA.
The quantity of endogenous GDNF secreted by noninfected astrocytes, or those infected with empty adenovirus was low (120716 pg/ml) at all time points tested in CM. The amount of endogenous GDNF was close to the detection limit of the assay (20 pg/ml) in the cellular pellet.
In astrocytes infected with 50 viral particles (vp)/cell of Ad-GFAP-GDNF, 0.370.05 ng/ml of GDNF was secreted in the CM per day. GDNF levels of 0.270.04, 0.470.07 and 0.370.08 ng/ml were detected in the cellular pellet at days 4, 6 and 8, respectively.
However, when astrocytes were infected with Ad-GFAP-GDNF at higher doses (500 and 10 3 vp/cell), 50-60 ng/ml of GDNF was secreted in the CM by 10 5 cells per day (Figure 1 ) (Po0.0001 for 500 vp; P ¼ 0.0008 for 10 3 vp as compared to control). At a dose of 5 Â 10 3 vp/cell, 70 ng/ml of GDNF was secreted in the CM from day 4 to day 6, and it declined thereafter (Figure 1 ) (Po0.0001 as compared to control). In cellular pellets, about 4074 ng/ml of GDNF was found at these three doses at all time points tested. From this result, two doses of virus, 500 and 5 Â 10 3 vp/cell, were chosen to infect the mesencephalic cells.
Mesencephalic cells infected with 500 and 5 Â 10 3 vp/ cell of Ad-GFAP-GDNF secreted 3079 and 80720 pg/ ml of GDNF in the the CM, respectively. In control cultures (cells noninfected by the virus), about 35 pg/ml of GDNF was found in the CM.
In cellular pellets, 0.570.1 and 0.870.12 ng/ml of GDNF were measured in cells infected with 500 and 5 Â 10 3 vp/cell, respectively, 6 days after infection. In cellular pellets of control cultures, 0.670.09 ng/ml of GDNF was found. These results indicate that recombinant GDNF was not effectively synthesized by the mesencephalic cells infected with Ad-GFAP-GDNF.
Survival of DA neurons. To test the effect of GDNF on the survival of neuronal cells, 10 4 mesencephalic cells were plated on a layer of nontransduced astrocytes, astrocytes infected with 10 3 vp/cell of Ad-GFAP-GDNF or onto collagen-coated coverslips (control).
When plated on transduced astrocytes, 457770 tyrosine hydroxylase (TH)-positive neurons were found. This was two-fold lower if plated on noninfected astrocytes (233723). The number of surviving THpositive neurons was lowest (114718) on collagencoated coverslips (Figure 2 ). Figure 1 GDNF levels in cultured astrocytes infected with recombinant virus. Primary astrocytes were infected with Ad-GFAP-GDNF at different doses. d1: 500 vp/cell; d2: 10 3 vp/cell; d3: 5 Â 10 3 vp/cell; C: control, noninfected astrocytes. In all, 50-60 ng/ml of GDNF was released by 10 5 cells per day with both doses d1 and d2. At a higher dose (d3), about 70 ng/ ml of GDNF was released by 10 5 cells/day until day 6 after infection. Then the quantity of GDNF decreased at day 8. *Po0.0001 d1 versus control at three times analyzed; **P ¼ 0.008, 0.0004, o0.0001 d2 versus control at three times analyzed, respectively; ***Po0.0001, o0.0001, 0.0002 d3 versus control at three times analyzed, respectively.
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In vivo experiments
The effect of striatal overexpression of GDNF on the DA neuron survival and motor function in a rat model of PD was investigated by direct in vivo delivery of the transgene, using recombinant Ad-GFAP-GDNF.
Body weight. Injection of large doses of recombinant GDNF protein has been found to cause loss of body weight in rats. 26 No significant differences in weight were observed among the treatment groups over the entire period of experimentation. Thus the quantity of transgenic GDNF detected in the striatum did not affect the body weight of rats. 9 vp/rat) were used to determine an optimal dose both in terms of level of GDNF expression and inflammatory reaction. GDNF expression was assessed by ELISA in striatum obtained from nonlesioned animals that were killed 10 days, 4, 6 and 12 weeks after vector injection. As shown in Table 1 , at doses of 10 8 and 5 Â 10 8 vp/rat, the striatal GDNF content was the highest at all times analyzed as compared to other doses. At a lower dose of the virus (10 7 vp/rat), GDNF levels were 10-fold lower than those measured in rats that had received 10 8 vp of virus, at all time points studied. At doses of 10 9 and 3 Â 10 9 vp/rat, 12-20 pg/mg GDNF protein was found (Table 1) in transduced striatum, but a marked, strong inflammatory reaction was observed (data not shown). However, the GDNF protein levels decreased with time at all doses used (Table 1) .
Analysis with semiquantitative competitive polymerase chain reaction (sqc-PCR) showed that the level of viral DNA in injected striatum (10 8 vp/rat) did not change between 10 days and 12 weeks after viral administration ( Figure 3) . From these results, we used 10 8 vp/rat in the following experiments.
GDNF expression in lesioned rats. The efficacy of adenovirus-mediated GDNF gene transfer was tested on a rat model of PD. 13 Adult rats were injected stereotaxically with 10 8 vp of Ad-GFAP-GDNF (G group) into the left striatum as described in Materials and methods. At 1 week after viral injection, rats were anesthetized and received stereotaxic injection of 6-OHDA. Striatum and substantia nigra (SN) were dissected out of animals killed at 4, 6 and 12 weeks after viral injection and the GDNF levels in these tissues were determined by ELISA.
As shown in Table 2 , the GDNF protein levels were 37-40 times higher (37.3 and 41 pg/mg corresponding to 70 and 75 ng of GDNF per striatum, respectively) in Ad-GFAP-GDNF-transduced striatum at 4 and 6 weeks as compared to both control groups (OHDA ¼ OH group; empty ¼ E group), as well as to the noninjected side. The GDNF quantity was decreased at 12 weeks (17.2 pg/mg corresponds to 35 ng of GDNF per striatum) after viral Figure 2 Survival of mesencephalic cells in culture. The survival TH ( þ ) neurons was two-fold higher on transduced astrocytes (G) than on noninfected cells (A, P ¼ 0.002) and four-fold higher as compared to control (C, P ¼ 0.0003). C: neurons on collagen-coated coverslips used as control; A: neurons on noninfected astrocytes; G: neurons on astrocytes infected with Ad-GFAP-GDNF. 8 vp/rat of Ad-GFAP-GDNF was unchanged from day 10 to week 12 (three animals per point). P ¼ 0.5, 4 weeks versus 10 days; P ¼ 0.9, 6 weeks versus 10 days; P ¼ 0.9, 12 weeks versus 10 days.
Degeneration of DA neurons prevented by Ad-GDNF NA Do Thi et al injection.
To explain the decline of GDNF levels in Ad-GFAP-GDNF-injected striatum at a later stage, sqc-PCR was performed to determine the relative quantity of the virus at different times after viral injection. As shown in Figure 4 , the viral DNA levels were unchanged during 12 weeks of experiment, which suggests a downregulation of GFAP promoter in vivo rather than a loss of injected viral DNA.
In the SN, the GDNF protein levels were similar in the injected side as compared to the noninjected side and in all groups of animals ( Table 2 ). The viral DNA levels were not detectable in the SN by sqc-PCR.
Amphetamine-induced rotation test. The impact of GDNF overexpression on the behavior of the animals was assessed during 12 weeks after viral vector injection. As early as 2 weeks after the striatal 6-OHDA lesion (3 weeks after viral injection), rats injected with Ad-GFAP-GDNF into the striatum began to display reduced amphetamine-induced rotations. As shown in Figure 5 , 3, 4, 6 and 12 weeks after Ad-GFAP-GDNF treatment, rats exhibited a significant reduction in GDNF protein levels (pg/mg total protein) from striatum and SN measured by ELISA in lesioned animals treated with Ad-GFAP-GDNF (10 8 vp/rat), with empty adenovirus (10 8 vp/rat) or in naive animals that did not receive treatment before inducing 6-OHDA lesion. Seven animals were used per point. GDNF protein levels decreased with time in transduced striatum (G group) and remained unchanged in the injected striatum of E and OH groups. The GDNF levels were similar in the SN (injected and noninjected side) of all groups. Values are means7s.e.m. *Po0.0001 different from noninjected side; #Po0.0001 G versus E group; Po0.0001 G versus OH group.
Figure 4 Viral DNA levels of injected striatum in lesioned rats at 4, 6 and 12 weeks after viral treatment. The relative quantity of viral DNA was similar during our experiment from 4 to 12 weeks (five animals per point). P ¼ 0.9, 6 weeks versus 4 weeks; P ¼ 0.6, 12 weeks versus 4 weeks. Figure 5 Motor performance of the animals using the drug-induced rotation test. Rats were injected with D-amphetamine (2.5 mg/kg, i.p.) and their behavior was recorded for 90 min. At 3, 4, 6 and 12 weeks after viral injection, rats injected with Ad-GFAP-GDNF (G group) exhibited a significant reduction in ipsilateral rotational behavior compared with control groups (OH and E groups). P ¼ 0.008, G versus OH group (3 weeks); P ¼ 0.2, G versus E group (3 weeks); Po0.0001, G versus E and OH groups (4 weeks); Po0.0001, G versus E and OH group (6 weeks); P ¼ 0.006, G versus E group (12 weeks); P ¼ 0.0002, G versus OH group (12 weeks).
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In rats injected with empty virus, the rotation score was not significantly different from that of the animals that received 6-OHDA alone at 3, 4 and 6 weeks after viral injection (P ¼ 0.08, 0.4 and 0.3, respectively).
Protection of DA neurons in the SN. Survival of DA neurons was analyzed throughout the SN as described in Materials and methods. Comparison of the percentage of the TH-positive cells in the SN (average results from the three levels analyzed) revealed that about 70% of DA neurons remained in the G group as compared to about 45% in the control groups at all three times examined (Po0.0001, 0.01 and 0.0004, 4, 6 and 12 weeks, respectively) ( Figures 6, 7a and b) . This result suggested that a significant protection of DA neurons was found in animals treated with Ad-GFAP-GDNF.
Immunoreactivity in the striatum. Following an injection of 6-OHDA into the striatum, there is an immediate toxic damage to the DA fibers and axons followed by a rapid degeneration of their terminals. 4, 27 We used NeuN staining to localize the lesion in the striatum (Figure 9d) , and immunohistochemistry for the TH to assess the extent of denervation induced by intrastriatal 6-OHDA lesions (Figure 8a and b) . The extent of denervation was prominent in the central and dorsal parts of the injected striatum in all animals analyzed. The intensity of THpositive fiber staining, measured by optical density, in the injected striatum (average results from the three levels analyzed) was similar in both E and OH groups (Figure 8b ). It was reduced by about 70-75% (Po0.0001) in the injected side versus the noninjected side at 4 weeks and by about 80-85% (Po0.0001) at 6 and 12 weeks. The TH intensity was slightly higher in animals of G group ( þ 7%) at 4, 6 and 12 weeks as compared to controls, but it did not reach statistical significance (P ¼ 0.2) (Figure 8a ).
Abundant TH immunoreactive profiles (dots) of different sizes (Figure 8c and f) were observed in the lesion sites of the striatum. Some of these patterns were scattered throughout the parenchyma in animals of G, OH and E groups. However, in animals treated with Ad-GFAP-GDNF (Figure 8c ), the number of these TH immunoreactive profiles was increased as compared to control animals at all three times analyzed (Figure 8f) . At higher magnification, we observed TH-positive fibers with numerous axonal varicosities which displayed different intensity of TH staining ( Figure 8d , compared with Figure 8g (control) ). In globus pallidus, we observed the TH immunoreactive area, which appears to correspond to the axonal sprouting of TH-positive fibers in animals treated with Ad-GFAP-GDNF vectors (Figure 7c ). The TH-positive fibers were also observed in the entopeduncular nucleus of these rats (Figure 7d ). These patterns were not seen in any of the animals of control groups.
The GDNF transgene expression in transduced striatum was visualized by anti-GDNF antibody. As shown in Figure 9a and b, the striatal astrocytes of animals treated with Ad-GFAP-GDNF were stained with GDNF antibody.
We also determined the effect of the viruses on the size of the striatum by analyzing the surface of 10 sections per brain between the coordinates AP þ 1.7 and AP þ 0.2. The injected striatal size was not modified in G (P ¼ 0.8), E (P ¼ 0.7) and OH (P ¼ 0.4) groups at 4 weeks as compared to the noninjected side. However, we observed a nonsignificant atrophy, 7% as compared to controlateral size, of the injected striatum of G (P ¼ 0.5) and E Figure 6 Rescue of TH immunoreactive neurons in the SN. Significant increase in the percentage of TH immunoreactive neurons was observed in lesioned rats treated with Ad-GFAP-GDNF (G group) compared with rats injected with empty adenovirus (E group) or with lesioned rats (OH group). Po0.0001, G versus E group (4 weeks); P ¼ 0.001, G versus OH group (4 weeks); P ¼ 0.01, G versus E group (6 weeks); P ¼ 0.003, G versus OH group (6 weeks); P ¼ 0.0004, G versus E group (12 weeks); Po0.0001, G versus OH group (12 weeks). Degeneration of DA neurons prevented by Ad-GDNF NA Do Thi et al (P ¼ 0.6) groups at 6 and 12 weeks. In the OH group, very mild atrophy was seen (4% as compared to the controlateral side) at 12 weeks, but not significant as assessed by one-way analysis of variance (ANOVA), P ¼ 0.6.
Inflammatory response. Injuries to the brain result in a rapid inflammatory reponse that typically involves recruitment and infiltration of different cell populations. Immunohistochemistry using CD4 and CD8 antibodies allows one to determine the localization of reactive lymphocytes. CD4 immunoreactive cells were most numerous at the injection sites of the adenoviral vector with or without transgene, and at the 6-OHDA lesion in all treatment groups (Figure 9e ). They were also scattered throughout the parenchyma and close to the blood vessels. A few CD8 immunoreactive cells were particularly concentrated at the injection sites of the adenoviral vector and around the 6-OHDA lesion (Figure 9f ). We did not observe more inflammation in G and E groups as compared to the OH group, with both CD4 and CD8 antibodies (Table 3) . Astrocytic response to injury was assessed by using an antibody against GFAP. Glial fibrillaly acidic protein, an intermediate filament protein, is expressed abundantly in astrocytes during development 28 of the CNS and in reactive astrocytes (astrogliosis) following CNS injury. 24, 25 Reactive astrocytes, characterized by a significant increase in the GFAP intensity, cellular hypertrophy and increase in the density of GFAP immunoreactive Figure 8 TH immunostaining of the striatum, 4 weeks after viral treatment. On the intact side, the TH staining intensity was high throughout the striatum (a, b, right side). After intrastriatal lesion, the TH staining was almost lost at the site of 6-OHDA injection (b, left side). By contrast, Ad-GFAP-GDNF-treated animals had a more lasting TH intensity on the ipsilateral side (a, left side). High-power magnification of boxed area in (b) showed that the axonal terminals in the striatum were degenerated at the lesion site (e, asterisk), whereas some spared terminals remained (arrow). In these GDNF-treated animals, numerous TH-positive axonal profiles (c, dots) and TH immunoreactive fibers with varicosities and sprouting (d, arrow) were seen in the denervated striatum. In the striatum of 6-OHDA lesioned animals, the TH-positive profiles (f) and TH immunoreactive fibers with varicosities (g) were less numerous. Scale bar represents (a, b) 200 mm and (c-g) 50 mm. Figure 9 Immunostaining of transduced striatum, 4 weeks after Ad-GFAP-GDNF treatment. At the injected site, a halo of GDNF was seen with GDNFpositive astrocytes (a); at low magnification astrocytes stained with GDNF antibody (b). Numerous cells stained with CD4 (e) and CD8 (f) at the injected site. In (d) the site of 6-OHDA lesion was stained by NeuN antibody. Inside the lesion, the neurons were degenerated, while around the lesion the nuclei of neurons were stained by NeuN. Reactive astrocytes were stained by GFAP antibody (c) at the injected site of the striatum. Scale bar represents (a) 35 Degeneration of DA neurons prevented by Ad-GDNF NA Do Thi et al processes, were detected throughout the ipsilateral striatum. The GFAP staining was particularly intense at the lesion with a dense network of cell bodies and processes in all study groups (Figure 9c ).
Discussion
The aim of the present study was to assess the ability of GDNF, expressed by an improved E1,E3/E4 defective recombinant adenovirus in which the GDNF gene is driven by a glial-specific promoter, to preserve the integrity of the nigrostriatal DA system (cell bodies, axonal terminals) and the normal motor function after administration of the virus into the striatum before inducing 6-OHDA lesion. Our interest was also to test the GFAP promoter for PD therapy since this promoter was described to direct specifically transgene expression in astrocytes. 24, 25 In our cell cultures, GDNF protein was not synthesized by the mesencephalic cells infected with the recombinant GFAP-GDNF adenovirus, whereas this trophic factor was produced and secreted by the transduced astrocytes (Figure 1 ). Morelli et al 29 observed that only cultured neocortical neurons, infected with a recombinant defective adenovirus vector encoding FasL under the control of the neuronal-specific promoter NSE (RAd-NSE-FasL), released the cytotoxic Fas ligand into the culture supernatant. Neurons transduced with a vector under the control of a glial-specific promoter (RAd-GFAP-FasL) were unable to release the FasL cytotoxic activity. Thus, the expression of the transgene was cell-type restricted when the transcription was directed from a glial-or a neuronal-specific promoter in the adenoviral vector.
In vivo, in a rat model of PD, immunohistochemical experiments, performed in the transduced striatum, demonstrated that the expression of the transgene (GDNF) was confined to astrocytes (Figure 9a and b) . This observation was supported by the results obtained from ELISA tests (Table 2) . After an intrastriatal injection of Ad-GFAP-GDNF, the GDNF protein levels were high in transduced striatum (37-41 pg/mg protein from 4 to 6 weeks; Table 2 ). At 12 weeks the quantity of GDNF protein decreased, whereas the levels of adenoviral DNA remained unchanged from weeks 4 to 12 ( Figure 4) . The decline of the transgene expression could result from the host immune responses to the vector in infected cells 30, 31 or due to the down regulation of the promoter. 12 In our study, the decline in the GDNF expression was unequivocally the result of a downregulation of the GFAP promoter rather than the loss of adenovirus-infected cells, since the quantity of viral DNA in the transduced striatum did not change during the experiment ( Figure  4 ). Using the RSV promoter to drive the expression of the GDNF, Choi-Lundberg et al 32 found that GDNF protein and GDNF DNA levels decreased simultaneously from weeks 1 to 7.
In our study, although the GDNF protein level decreased, it remained relatively high at 12 weeks (17 pg/mg protein; Table 2 ). Armentano et al 33 and Dedieu et al 17 showed that the deleted E1,E3/E4 recombinant adenoviruses were unable to sustain a strong and stable transgene expression when under the control of the CMV and RSV promoters. Thus the longlasting presence of the recombinant GDNF in our experiment cannot be attributed solely to the E1,E3/E4 Ad-GFAP-GDNF backbone. The prolongation of the GDNF expression we obtained was probably the consequence of the activity of the GFAP promoter. Despite a downregulation of the GFAP promoter at 12 weeks, its remaining activity would still be sufficient to induce the late and high-level expression of the transgene in the astrocytes. In four animals we even observed GDNF expression in the transduced striatum 5 months after Ad-GFAP-GDNF injection (unpublished results).
In addition, the recombinant E1,E3/E4 defective adenovirus used in the present study appeared to be weakly immunogenic in the brain. We did not observe an increased inflammation in the lesioned brains after GFAP-GDNF or empty virus injection as compared to the OHDA-injected animals (Table 3) . Moreover, the transduced striatum sizes were not reduced. These results suggest that this is an improvement of the adenoviral vector compared to the first-generation adenovirus used previously by our group. 11 Another important result was that approximately 70% (as compared to about 45% in the controls) of the nigral DA neurons were still present at 12 weeks when the recombinant Ad-GFAP-GDNF had been injected into the striatum, 1 week before inducing the intrastriatal 6-OHDA lesion. The ratios of protected neurons did not change with time from week 4 to week 12 after the viral treatment ( Figure 6 ). As the protection of the DA neurons was not complete, it is possible that the recombinant GDNF, synthesized by striatal transduced astrocytes and transported by retrograde axonal transport, was not sufficient in the SN ( Table 2 ). The results obtained in this work are consistent with previous studies by our group 11 and others 9,14 using Ad/AAV-GDNF injected in the striatum. In addition, these authors 9, 11, 14 found (1) that the intensity of the TH immunoreactivity was increased in the injected striatum, as compared to control 9, 11, 14 and (2) that the axonal sprouting was present in the striatum and the globus pallidus. 9 In our rats treated with Ad-GFAP-GDNF, although the sprouting was observed in the striatum and the globus pallidus (Figures 7 and 8) , the intensity of the striatal TH staining was not modified in the injected side. This may be due to the low 
Number of animals from G, E and OH groups where the inflammation was produced in the brains from 4 to 12 weeks after treatment. For each animal, 10 CD8 and CD4-stained sections were examined and scored as described in Materials and methods. First values in each column (G, E, OH) were estimated on CD8-stained sections, and second values (italic) were estimated on CD4-stained sections.
Degeneration of DA neurons prevented by Ad-GDNF NA Do Thi et al magnitude of axonal sprouting, which would not be sufficient to induce a significant increase of the TH in the lesioned striatum. However, a downregulation of the TH protein in the lesioned striatum was reported when the delivery of GDNF was high and lasted for a long period. 34 Thus, in our study, the lack of increase in striatal TH staining was probably the result of a high and long-lasting expression of the GDNF transgene (Table 2) .
Furthermore, we showed that the rotational behavior induced by amphetamine decreased with time ( Figure  5) . 35 A similar decrease was previously described by Connor et al 14 and Kozlowski et al 15 after injection of Ad-GDNF into the striatum 14 or in the SN. 15 This was accompanied by an increased expression of fos protein, as assessed by immunostaining. 14, 15 Their results reflect an enhanced release of dopamine in the denervated striatum 14, 15 after Ad-GDNF treatment. Thus, the decreased rotational behavior in animals treated with Ad-GFAP-GDNF in the present work ( Figure 5 ) may have been caused by increased dopamine release from surviving nerve terminals of the striatum. Nevertheless, we do not know whether Ad-GFAP-GDNF affects the release of dopamine by striatal fibers in denervated striatum or by rescued nigral neurons that project to the lesion side. This question will be investigated in our next study.
In conclusion, these experiments provide important evidence that a recombinant adenovirus containing the GDNF gene, driven by a glial-specific promoter (GFAP), increased the survival of nigral DA neurons and improved the rotational behavior in a rat model for PD. This effect can probably be attributed to the release of GDNF by the transduced striatal astrocytes and by retrograde axonal transport of the GDNF molecule, via striatal nerve terminals to the SN, to rescue DA cell bodies there. Thus transduced astrocytes play an important role in the protection of the DA neurons. In our experiments, the virus used was not only functionally efficient but also clearly appeared safer than the first-generation adenovirus used in a previous study by our group.
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Further studies will have to address the influence of other promoters in driving the GDNF gene, such as neuron-specific promoter (NSE) to direct the transgene expression to neurons, or PGK and EF1a, ubiquitous promoters. Such studies will allow us to choose the most appropriate promoter to direct the transgene expression in adenoviral vectors for the treatment of different diseases.
Materials and methods

Preparation of Ad-GFAP-GDNF virus
A recombinant adenovirus deleted in the E1, E3 and E4 regions of the type 5 adenovirus, carrying sequences encoding for rat GDNF under the control of the promoter for GFAP and with the SV40 polyadenylation signal in the late orientation (Ad-GFAP-GDNF) was constructed.
The expression cassette was introduced into the E1 region of an 'adenoviral plasmid', containing the Ad5 genome deleted in the E1, E3 and E4 regions, by homologous recombination in Escherichia coli. 36 The virus was generated and amplified in the IGRP2 packaging cell line. 16 GFAP-GDNF shuttle plasmid. The 636 bp cDNA of the rat GDNF was amplified from cultivated astrocytes by RT-PCR as previously described. 11 In addition, a Kozak consensus sequence 37 was introduced by PCR at the 5 0 UTR for optimal translation. The cDNA was sequenced on both strands and found to be identical to that published by Lin et al.
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A plasmid containing the sequence of SV40 late polyadenylation signal (pSK-SV40 polyA) was obtained from Drs Branellec and Mahfoudi (Aventis). The correct sequence of the polyA region was confirmed by sequencing.
A partial expression cassette with the cDNA for GDNF and the polyadenylation signal from SV40 polyA (late orientation) was obtained by restriction enzyme digestion with AvrII and SacI of pLTRIX-GDNF, 11 and with BglII of PSK-SV40 polyA followed by blunt-end ligation. The GDNF-pA sequence was then digested for subsequent blunt-end ligation with the specific promoters.
The plasmid containing the human GFAP promoter, pgfa2Lac-1, was obtained from Dr Michael Brenner, NIH, Bethesda, MD, USA. The plasmid contains sequences from À2163 to þ 47 of the promoter for human GFAP, with the initiating ATG mutated to TTG. The GFAP promoter was obtained from this construct by BglII and BamHI digestion, and ligation to plasmid GDNF-pA. The expression cassette GFAP-GDNF-pA was obtained from this plasmid by HindIII and SalI digestion followed by blunt-end ligation to plasmid pXL3234.
Plasmid pXL 3234 is a shuttle plasmid containing Ad5 ITR-psi sequences from position 1 to 385 and pIX sequences from position 3447 to 4421. It was digested by EcoRV or AvrII and SalI in order to introduce the expression cassette of interest in between the ITR-psi and pIX sequences.
The entire expression cassette as well as the junctions between the cassette and the ITR-psi and pIX were sequenced and found to correspond to the expected sequence.
Plasmid containing recombinant adenoviral genomes (RAG). The shuttle plasmid containing the entire expression cassette with the transgene GDNF was introduced into E. coli JM83 containing pXL 3412, 36 which contains the Ad5 genome deleted in the E1 (385-3328)/E3 (28592-30470/E4 (33423-35356) regions. 17 Inserted in the E1 region is an expression cassette RSV-lacZ/SV40polyA early. 39 Homologous recombination results in the exchange of the lacZ expression cassette for the expression cassette bearing the transgene of interest (GDNF). Once the adenoviral plasmid bearing the therapeutic gene of interest was obtained, the plasmid was transformed into E. coli DH1 in order to prevent potential recombination between repeated sequences.
Recombinant adenovirus and stock preparation. DNA from RAG plasmids was prepared by the cesium chloride technique (Maxiprep, Gibco BRL). Viruses were generated by transfection of PacI-digested RAG DNA into the packaging cells IGPR2 16 using lipofectamine (Gibco BRL).
IGRP2 cells were grown in the presence of 10 À8 M dexamethazone (Sigma). Cells were harvested 8-10 days
Degeneration of DA neurons prevented by Ad-GDNF NA Do Thi et al post-transfection, freeze/thawed repeatedly for lysis and the viral supernatants (transfection stage) obtained were stored at À801C until further amplification. After a second round of amplification, the viruses were purified by CsCl gradient ultracentrifugation and desalted on a PD10 column (Pharmacia). The GFAP-GDNF viral stock was eluted in phosphate-buffered saline (PBS), aliquoted and stored at À801C in PBS-10% glycerol.
Titration of the viral stock was performed by anionexchange HPLC and expressed as the number of vp/ml. 40 The titer of the Ad-GFAP-GDNF was 1.02 Â 10 12 vp/ml. The empty adenovirus, used as control, contains no promoter and no transgene, and was a gift from L Ferrero (Gencell). The titer of the empty virus was 1 Â 10 12 vp/ml.
In vitro experiments
IGRP2 cells 16 were grown in modified Eagle's medium (MEM, Gibco BRL, France) supplemented with 10% fetal calf serum (FCS', Hyclone, Erembodegem-Aalst, Belgium) in T-150 or T-500 flasks (Nunc). Geneticine (Gibco BRL) was added to the medium at a final concentration of 350 mg/ml.
Astrocyte cultures were prepared from the striatum of Sprague-Dawley rat embryos (E15). Cells were cultivated in Dulbecco's modified Eagle's medium (DMEM, Gibco) with 10% FCS. 41 Mesencephalic cells were prepared from SpragueDawley rat embryos (E14). Cells were cultivated in N2-supplemented DMEM/Ham F12 on collagen-coated 24-well plates.
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All cell lines and primary cultures were incubated in a 5% CO 2 atmosphere at 371C. Astrocytes and mesencephalic cells were seeded to 24-well plates at 10 5 cells/ well. The cells were infected with Ad-GFAP-GDNF or empty adeno-virus at different doses (see Results) for 2 h at 371C. The medium was replaced with fresh medium (1 ml/well) 24 h before collecting the CM.
In some experiments, the DA neuron survival rate was quantified. Mesencephalic cells (10 4 ) were plated onto collagen-coated coverslips or on a layer of astrocytes previously infected with Ad-GFAP-GDNF. After 7 days, the cells were fixed with 4% paraformaldehyde in PBS and processed for TH immunohistochemistry. The number of TH immunoreactive cells were counted directly under the microscope using three wells for each time, and experiments were repeated twice.
In vivo experiments
A total of 100 young female Sprague-Dawley rats (200-220 g; Janvier, France) were used in these experiments. Rats were anesthetized with an intraperitoneal injection of Rompun 2% (Bayer AG, Leverkusen) and Ketamine 1000 (Virbac, France), v/v, 1 ml/kg before placing on stereotaxic frames (Kopf Instruments, CA, USA). All injections were made using 10 ml Hamilton microsyringes and microinjection pump CMA/100. The needle of the Hamilton syringe was inserted into the opening of one end of the fitting polyethylene tubing (0.0015 00 Â 0.043 00 Â 0.014 00 ; Carlsborg, WA, USA). A 34G needle (Cooper's Needle Works Ltd) was introduced into the opening of the other end of the tube and sealed by silicone glue.
The Ad-GFAP-GDNF and the empty adenoviruses (control), diluted in PBS, were injected into six sites (1 ml per site) of the left striatum (STR) at the coordinates (1) AP: þ 1.8 mm; L: 2.5 mm; V: 5 mm/V: 4.6 mm; (2) AP: þ 0.6 mm; L: 2.00 mm; V: 5 mm/V: 4.6 mm; (3) AP: þ 0.6 mm; L: 3.2 mm; V: 5 mm/V: 4.6 mm, at a speed of 0.25 ml/min.
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At 1 week after viral injection, all animals, except those used in preliminary experiments (see Results), were anesthetized and received stereotaxic injection of 5 ml of 6-OHDA-HCl (Sigma, 4 mg/ml in ice-cold ascorbate saline) at a speed of 0.5 ml/min, into their left striatum at the following coordinates: AP: þ 1.2 mm from bregma; L: þ 2.5 mm lateral to midline; V: À5, 4.6 and 4.2 mm ventral to dural surface, three-site lesion. 11 Animals were deeply anesthetized on various time points between 10 days and 12 weeks after viral delivery with pentobarbital and perfused with 100 ml isotonic saline, followed by 300 ml of ice-cold 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.4. Brains were removed and postfixed for 2 h in the same solution and then transferred to 15% sucrose in 0.1 M phosphate buffer (two changes) at 41C overnight. Brains were then frozen in dry-ice-cooled isopentane (À451C) and stored at À801C for further histological analysis. Some brains were freshly frozen directly in dry-ice-cooled isopentane and stored at À801C for CD4 and CD8 investigation. For these two antibodies, cryostat sections were fixed with alcohol at À201C for 10 min before antibody staining.
The striatum and the SN of some brains were dissected out, freshly frozen in nitrogen liquid, and stored at À801C for ELISA.
Histological analysis
Cryostat sections (14 mm) were preincubated with 10% of normal goat serum and 0.2% of Triton (Sigma) in PBS for 30 min at room temperature and then incubated with a 1:500 dilution of rabbit anti-TH antibody, 43 rabbit anti-GFAP antibody (Dako, Denmark), mouse anti-Neu-N antibody (Chemicon international, CA, USA) or a 1:100 dilution of mouse CD4 or CD8 antibodies (Cedarlane, Canada), rabbit anti-GDNF antiboby (Santa-Cruz Biotechnology) for 2 h. Appropriate biotinylated secondary antibodies (Vector laboratories, Burlingame, CA, USA) directed against the species in which primary antibody was raised were used in all cases, 1 h at room temperature. The sections were then incubated with avidin-biotin-peroxidase complex for 1 h (ABC; Vector Laboratories, Burlingame, CA, USA). The reaction was visualized using 3,3-diaminobenzidine, SG or VIP as a chromogen.
The number of TH immunoreactive cell bodies present in the SN (excluding the ventral tegmental area) was determined in every fifth serial section between the coordinates AP: À4.3, À5.3 and À5.8 mm from bregma.
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The DA neuron survival was calculated as the percentage of TH immunoreactive cells counted in lesioned SN to those in controlateral nonlesioned SN.
The denervation of injected striatum was analyzed as follows. All images of striatum were taken with a camera (Nikon) and stocked on CD-rom, using Samba software. The intensity of TH staining of the striatum was determined using the Aida 2.43 software. For each animal, the whole cross-sectional area of the striatum was outlined on the computer screen, and the optical density and the surface were measured at three levels: AP: þ 1.7; AP: þ 1.2; AP: þ 0.2 relative from bregma (four sections per level). The intensity of TH staining and the surface of the injected striatum were expressed as a percentage of the controlateral side.
The inflammation of injected striatum was determined semiquantitatively on CD4/CD8 immunostained sections. The intensity of the staining was directly estimated under the microscope in four regions: at the injection sites (virus/6-OHDA), in the perenchyma, in the perivascular zones and in the cortical surface layers. Inflammation was scored as follows: (À) staining from noninjected animals, (7) very little staining (background), ( þ ) little staining, ( þ þ ) moderate staining, ( þ þ þ ) strong staining, ( þ þ þ þ ) very strong staining. A total of 10 immnunostained sections were examined for each brain. The results were expressed as the average estimation for each animal. The number of animals in which the treatment produced inflammation is reported in Table 3 .
Biochemical analysis
The levels of GDNF in cell cultures and in tissues were determined by ELISA using GDNF Emax ImmunoAssay system kit (G 7621; Promega, Madison, WI, USA). Tissues from the striatum and the SN were homogenized at a tissue concentration of 40 mg/ml (wet weight per volume) in lysis buffer (Tropix) in the presence of an EDTA-free protease inhibitor cocktail (Boehringer). For pellets of cell cultures, 50 ml of lysis buffer was used. After centrifugation (15 min, 5000 r.p.m., at 41C), the supernatant was frozen at À801C for further ELISA analysis and for Bradford analysis 44 for the determination of total protein concentration. The level of GDNF was expressed as pg of GDNF per mg of total protein. The pellets were used to determine the viral DNA levels.
Semiquantitative competitive polymerase chain reaction 
Behavioral analysis
The injected animals were tested for amphetamineinduced turning, 3, 4, 6 and 12 weeks after viral injection. Motor asymmetry was monitored in automated rotometer bowls (depth ¼ 34 cm, diameter ¼ 26 cm; Imetronic, Bordeaux, France) for 90 min after an injection of D-amphetamine sulfate (Sigma, 2.5 mg/kg, i.p.). Rotational behavior was recorded. A net rotation asymmetry score for each test was calculated by subtracting turns contralateral to the 6-OHDA lesion from turns ipsilateral to the lesion.
Statistical analysis
All values were expressed as the mean7s.e.m. (standard error of the mean). Differences between groups were analyzed by using ANOVA followed, when significant (Po0.05), by t-test.
